Human papillomavirus Associated Cancer Pipeline, FDA Approvals, Unmet Needs, Preclinical and Discovery Stage Product, and Companies 2024 (Updated)

DelveInsight's, "Human papillomavirus Associated Cancer Pipeline Insight 2024" report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Human papillomavirus (HPV) Associated Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the Human papillomavirus Associated Cancer Pipeline Report
• DelveInsight's Human papillomavirus Associated Cancer pipeline report depicts a robust space with 50+ active players working to develop 50+ pipeline therapies for Human papillomavirus Associated Cancer treatment.
• The leading Human papillomavirus Associated Cancer Companies working in the market include Turnstone Biologics, Advaxis, AstraZeneca, VLP The Vaccines Company SL, Voltron Therapeutics Inc., Rubius Therapeutics, Inovio Pharmaceuticals, Bristol-Myers Squibb, Precigen Inc., Privo Technologies, ViciniVax BV, Avalia Immunotherapies, BlueSky Immunotherapies, Cellid Co Ltd, Cue Biopharma, Cullinan Oncology, Genexine, EyeGene, Hookipa Pharma, Immunomic Therapeutics, ISA Pharmaceuticals BV, SQZ Biotechnologies, and others.
• Promising Human papillomavirus Associated Cancer Therapies in the various stages of development include TGN-S11, Pembrolizumab, MEDI0457, and others.
• May 2024:- Toragen Inc.- This is an open-label, non-randomized, Phase I, dose escalation/dose expansion study in cohorts of patients with relapsed, resistant, or metastatic HPV-associated cancers. The Expansion Phase will begin in parallel one dose level lower than the highest dose deemed safe in the Dose Escalation in combination with a PD-1 checkpoint blockade.
• May 2024:- Marengo Therapeutics Inc.- A Phase 1/2, First-in-Human, Open-Label, Dose Escalation and Expansion Study of STAR0602, a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule, in Subjects With Unresectable, Locally Advanced, or Metastatic Solid Tumors That Are Antigen-rich (START-001).
• May 2024:- TScan Therapeutics, Inc.- A Phase 1 Basket Study Evaluating the Safety and Feasibility of T-Plex, Autologous Customized T Cell Receptor-Engineered T Cells Targeting Multiple Peptide/HLA Antigens in Participants With Antigen-positive Locally Advanced (Unresectable) or Metastatic Solid Tumors.

Request a sample and discover the recent advances in Human papillomavirus Associated Cancer @ Human papillomavirus Associated Cancer Pipeline Outlook Report- https://www.delveinsight.com/sample-request/human-papillomavirus-hpv-associated-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Human papillomavirus Associated Cancer Overview
Human papillomavirus (HPV) infection is linked with several cancers such as cancer cervix, vagina, head and neck, anal, and carcinomas. Although there is a proven association of HPV with these cancers, questions regarding HPV testing, vaccination, and treatment of HPV-related cancers continue to remain unanswered. The present article provides an overview of the HPV-associated cancers.

The HPV infects squamous epithelial cells, which have the capacity to proliferate, and get access to basal cell during trauma or abrasion. In the basal cells, HPV infection induces the expression of viral genes that helps in the viral replication. The interaction of HPV with the host cells occurs via surface receptors such as heparin sulfate proteoglycans and alpha 6 integrins. The early proteins E1 and E2 are required for the initiation of replication. The protein E2, being the transcriptional repressor of E6 and E7, controls the expression of E6 and E7.

Human papillomavirus Associated Cancer Emerging Drugs Profile

• STP909: Sirnaomics Inc
STP909 comprises siRNA targeting human papillomavirus (HPV) sequences formulated with our PNP delivery platform for intravenous and topical administration. Company developing STP909 as a prophylactic vaccine for prevention of cervical cancer and other disease caused by HPV.

• RTX-321: Rubius Therapeutics
RTX-321 is an allogeneic, off-the-shelf aAPC therapy product candidate that is engineered to induce a tumor-specific immune response by expanding antigen-specific T cells. RTX-321 expresses hundreds of thousands of copies of an HPV peptide antigen bound to major histocompatibility complex (MHC) class I proteins, the costimulatory molecule 4-1BBL and the cytokine IL-12 on the cell surface to mimic human T cell-APC interactions.

• BVAC-C: Cellid Co Ltd
BVAC-C uses HPV type 16/18's carcinogen gene, E6/E7's recombination gene as antigen to apply on cervical cancer, head and neck cancer, anal cancer, and sex organ cancer caused by HPV infection. CeliVax-based pipeline, BVAC-C, completed phase-I clinical trial to check safety and it is currently undergoing phase-II clinical trial to check effectiveness.

• GX-188E: Genexine Inc
GX-188E is a DNA therapeutic vaccine fused with encoding both E6 and E7 antigens as well as the extracellular domain of Flt3L to target and activate dendritic cells. GX-188E has ability to induce a tumor-specific CD8+ immune response and functional activity to eliminate target cells against high-grade cervical intra-epithelial neoplasms (CIN3, carcinoma in-situ). A phase 1b/2 clinical trial for the cervical cancer patients to evaluate safety, tolerability and efficacy is currently ongoing.

• ITI-2000: Immunomic Therapeutics Inc
ITI-2000 provides an UNITE platform address for HPV+ cancers. The oncogenes E6 and E7 in both HPV 16 and HPV 18 strains are well proven to be immunogenic, providing the support to develop this product. ITI-2000, delivered by needle and syringe as a self-amplifying construct, will be indicated for HPV-positive cancers.

Learn more about Human papillomavirus Associated Cancer in clinical trials @ Human papillomavirus Associated Cancer Drugs- https://www.delveinsight.com/sample-request/human-papillomavirus-hpv-associated-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Human papillomavirus Associated Cancer Therapeutics Assessment
There are approx. 50+ key companies which are developing the therapies for Human papillomavirus (HPV) Associated Cancer. The companies which have their Human papillomavirus (HPV) Associated Cancer drug candidates in the most advanced stage, i.e. Phase III include Advaxis.

DelveInsight's Human papillomavirus Associated Cancer pipeline report covers around 50+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Discover more about Human papillomavirus Associated Cancer in development @ Human papillomavirus Associated Cancer Clinical Trials- https://www.delveinsight.com/sample-request/human-papillomavirus-hpv-associated-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Human papillomavirus Associated Cancer Companies
Turnstone Biologics, Advaxis, AstraZeneca, VLP The Vaccines Company SL, Voltron Therapeutics Inc., Rubius Therapeutics, Inovio Pharmaceuticals, Bristol-Myers Squibb, Precigen Inc., Privo Technologies, ViciniVax BV, Avalia Immunotherapies, BlueSky Immunotherapies, Cellid Co Ltd, Cue Biopharma, Cullinan Oncology, Genexine, EyeGene, Hookipa Pharma, Immunomic Therapeutics, ISA Pharmaceuticals BV, SQZ Biotechnologies, and others.

Human papillomavirus (HPV) Associated Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Intravenous
• Subcutaneous

Human papillomavirus Associated Cancer Products have been categorized under various Molecule types such as
• Small molecule
• Gene Therapy
• Cell Therapy
• Immunotherapy

To know more about Human papillomavirus Associated Cancer, visit @ Human papillomavirus Associated Cancer Segmentation- https://www.delveinsight.com/sample-request/human-papillomavirus-hpv-associated-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Human papillomavirus Associated Cancer Pipeline Report
• Coverage- Global
• Human papillomavirus Associated Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Human papillomavirus Associated Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Human papillomavirus Associated Cancer Companies- Turnstone Biologics, Advaxis, AstraZeneca, VLP The Vaccines Company SL, Voltron Therapeutics Inc., Rubius Therapeutics, Inovio Pharmaceuticals, Bristol-Myers Squibb, Precigen Inc., Privo Technologies, ViciniVax BV, Avalia Immunotherapies, BlueSky Immunotherapies, Cellid Co Ltd, Cue Biopharma, Cullinan Oncology, Genexine, EyeGene, Hookipa Pharma, Immunomic Therapeutics, ISA Pharmaceuticals BV, SQZ Biotechnologies, and others.
• Human papillomavirus Associated Cancer Therapies- TGN-S11, Pembrolizumab, MEDI0457, and others.

For further information on the Human papillomavirus Associated Cancer Pipeline Therapeutics, reach out @ Human papillomavirus Associated Cancer Products Development- https://www.delveinsight.com/sample-request/human-papillomavirus-hpv-associated-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Introduction
2. Executive Summary
3. Human papillomavirus (HPV) Associated Cancer: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Human papillomavirus (HPV) Associated Cancer - DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. Axalimogene filolisbac: Advaxis
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. PRGN-2009: Precigen PII
12. Drug profiles in the detailed report…..
13. Mid Stage Products (Phase II)
14. HB-200: Hookipa Pharma Inc
15. Drug profiles in the detailed report…..
16. Early Stage Products (Phase I)
17. RTX 321: Rubius Therapeutics
18. Drug profiles in the detailed report…..
19. Preclinical and Discovery Stage Products
20. Drug name: Company name
21. Drug profiles in the detailed report…..
22. Inactive Products
23. Human papillomavirus (HPV) Associated Cancer Key Companies
24. Human papillomavirus (HPV) Associated Cancer Key Products
25. Human papillomavirus (HPV) Associated Cancer - Unmet Needs
26. Human papillomavirus (HPV) Associated Cancer - Market Drivers and Barriers
27. Human papillomavirus (HPV) Associated Cancer - Future Perspectives and Conclusion
28. Human papillomavirus (HPV) Associated Cancer Analyst Views
29. Human papillomavirus (HPV) Associated Cancer Key Companies
30. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.